BCM
AXSM icon

Bayesian Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Bayesian Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-8,992
Closed -$628K – 752
2023
Q3 		$628K Buy
+8,992
New +$672K 0.07% 321
2023
Q2 		– Sell
-7,324
Closed -$452K – 796
2023
Q1 		$452K Buy
+7,324
New +$481K 0.06% 416
2022
Q2 		– Sell
-5,900
Closed -$244K – 783
2022
Q1 		$244K Buy
+5,900
New +$183K 0.04% 592

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bayesian Capital Management's AXSM Position: Q4 2023 in Review

Bayesian Capital Management sold out of Axsome Therapeutics (AXSM) in Q4 2023, closing a stake of 8,992 shares — an estimated $628K sold.

Bayesian Capital Management first reported a position in AXSM in Q1 2022 and held it in 3 quarters. The position peaked at $628K in Q3 2023. 244 funds tracked by Wall St. Rank hold AXSM as of Q4 2023.

  • Bayesian Capital Management reported no remaining Axsome Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Bayesian Capital Management sold 8,992 Axsome Therapeutics shares in Q4 2023, an estimated $628K.
  • Bayesian Capital Management first reported a position in Axsome Therapeutics in Q1 2022 and held it in 3 quarters.
  • Bayesian Capital Management's Axsome Therapeutics position peaked at $628K in Q3 2023.
  • 244 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2023.

Based on Bayesian Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.